Celltrion Launches Avtozma IV Formulation in the U.S.

Celltrion, Inc. announced that Avtozma (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.

Avtozma IV is approved for all same indications as the reference product Actemra  (tocilizumab), including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), coronavirus disease (COVID-19), and cytokine release syndrome (CRS).

Avtozma IV will be available in all the same formulations currently provided by Actemra IV. The available presentations are 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL) in single-dose vials.

Avtozma IV will be supported by a comprehensive patient support resources for healthcare providers and patients, and copay support for eligible commercial patients prescribed Avtozma IV.

“The launch of Avtozma IV reinforces Celltrion’s strong commitment to providing physicians and patients with access to high-quality treatment options for serious immune-mediated diseases and to supporting the sustainability of the U.S. healthcare system,” said Thomas Nusbickel, Chief Commercial Officer of Celltrion USA. “It also strengthens our immunology portfolio, expanding beyond TNF-α and IL-12/23 inhibitors, now including an IL-6 inhibitor, broadening coverage across inflammatory pathways and enhancing our ability to address a broader range of patient needs.”